COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $284.8 million in 78 projects around the world.











focused on new classes


The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More

Spotlight on Science

Vedanta Biosciences’ new VE303 drug will prevent live-threatening C. difficile infections by boosting the body’s microbiome

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video




UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners





Live Webinar: GARDP/REVIVE – Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance


Stellenbosch, South Africa

2020 Drug Discovery & Development Centre (H3D) Symposium: Celebrating a Decade of Infectious Diseases Drug Discovery and Development in Africa



BARDA AMR Vaccine Public Workshop: Vaccines against AMR Threats


  • 02.22.2021  |  CARB-X is funding The University of Queensland to develop a new drug targeted to low- and middle-income countries that would breathe new life into existing readily-available antibiotics in the fight against drug-resistance full release

  • 02.03.2021  |  CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria full release

  • 02.01.2021  |  CARB-X is funding the development of Avails Medical’s rapid antibiotic susceptibility testing technology to identify the most effective antibiotic therapy for serious blood infections full release

See All News

In The News

  • 02.17.2021  |  The next pandemic? It may already be upon us full story

  • 02.17.2021  |  Biden must act quickly to defeat another pandemic full story

  • 02.11.2021  |  Do we need a Netflix for Antibiotics? full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.